Inhalation Sciences technology behind 5 research posters at 2018’s Society of Toxicology (SOT) Annual conference
Inhalation Sciences technology was instrumental to the research of five scientific posters at SOT, San Antonio, US, March 11-15, including three abstracts from Karolinska Institutet (KI) Institute of Environmental Medicine on advanced in vitro nanoparticle research.
As well as KI’s three posters, two other ISAB clients will present findings achieved using PreciseInhale, which will be on show at Booth 432 at the Conference. ISAB CEO Fredrik Sjövall: “Five posters at SOT underlines how versatile and innovative PreciseInhale is, and how it is being embraced by world-class toxicology as well as pharmaceutical researchers. We’re delighted.”
The three KI posters are all co-authored by Lena Palmberg (Associate Professor, lung and airway research, KI, Institute of Environmental Medicine) and her team (J. Ji, S. Upadhyay, V. Kessler and G. Seisenbaeva) and ISAB CSO Per Gerde.
Associate Prof Lena Palmberg: “Cost-effective and very precise, ISAB technology gives toxicologists and environmental researchers precise in vitro results that closely mirror in vivo. Culturing 3D-models in an Air Liquid Interface mimics the uptake of substances into the lung more exactly than conventional cell culturing.”
The three posters are: (1.) Cell line based in vitro models of normal and chronic bronchitis-like airway mucosa to study toxic potential of aerosolized palladium nanoparticles. (2.) Multicellular Human Bronchial Models Exposed to Diesel Exhaust Particles Induce Inflammation, Oxidative Stress, and Macrophage Polarization and (3). Assessment of Inflammatory and Oxidative Stress Response in Human Primary Bronchial Epithelial Cells Cultured in Air-Liquid Interface following Aerosolized Carbon Nanoparticle Exposure.
For more information about Inhalation Sciences please contact:
Fredrik Sjövall, CEO
Email: fredrik.sjovall@inhalation.se
Phone: +46 (0)70 64 508 75
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when we breathe them in.